转移性去势抵抗性前列腺癌的细胞毒性化疗经验。
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
机构信息
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA.
出版信息
Urol Clin North Am. 2012 Nov;39(4):573-81. doi: 10.1016/j.ucl.2012.07.012.
Abstract
This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area. In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
摘要
本文回顾了转移性去势抵抗性前列腺癌（mCRPC）化疗的初步经验，并概述了该领域正在进行的一些临床试验。此外，作者还概述了回顾性分析随机试验中接受紫杉烷类化疗的患者的结局的现有知识。这些数据旨在为医生和患者提供关于 mCRPC 男性结局的一般概念，以促进临床决策以及临床试验的设计和评估。
相似文献
1
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Urol Clin North Am. 2012 Nov;39(4):573-81. doi: 10.1016/j.ucl.2012.07.012.
2
Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Eur Urol Focus. 2019 May;5(3):369-380. doi: 10.1016/j.euf.2017.11.009. Epub 2017 Dec 21.
3
Controversies in chemotherapy of prostate cancer.
Front Radiat Ther Oncol. 2002;36:72-80. doi: 10.1159/000061331.
4
Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int. 2006 Feb;15(81):6-7.
5
Which drug combination for hormone-refractory prostate cancer?
Expert Opin Pharmacother. 2005 Apr;6(4):667-70. doi: 10.1517/14656566.6.4.667.
6
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
7
Chemotherapy-based treatment for castration-resistant prostate cancer.
J Clin Oncol. 2011 Sep 20;29(27):3686-94. doi: 10.1200/JCO.2010.34.3996. Epub 2011 Aug 15.
8
Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16.
9
Update in the management of patients with hormone-refractory prostate cancer.
Curr Opin Urol. 2005 May;15(3):157-62. doi: 10.1097/01.mou.0000165548.87039.ff.
10
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Cancer Chemother Pharmacol. 2013 Nov;72(5):1055-61. doi: 10.1007/s00280-013-2291-x. Epub 2013 Sep 17.
本文引用的文献
1
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
2
Chemotherapy in patients with castration-resistant prostate cancer.
Eur J Cancer. 2009 Sep;45 Suppl 1:161-71. doi: 10.1016/S0959-8049(09)70029-2.
3
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Ann Oncol. 2008 Oct;19(10):1749-53. doi: 10.1093/annonc/mdn288. Epub 2008 May 16.
4
Chemotherapy in hormone-refractory prostate cancer.
BJU Int. 2008 Mar;101 Suppl 2:11-5. doi: 10.1111/j.1464-410X.2007.07485.x.
5
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
J Clin Oncol. 2008 Jan 10;26(2):242-5. doi: 10.1200/JCO.2007.12.4008.
6
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Clin Cancer Res. 2007 Nov 1;13(21):6396-403. doi: 10.1158/1078-0432.CCR-07-1036.
7
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Cancer. 2008 Jan 15;112(2):326-30. doi: 10.1002/cncr.23163.
8
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8.
9
Recent progress in management of advanced prostate cancer.
Oncology (Williston Park). 2005 Apr;19(5):631-6.
10
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28.
Zotero 插件